Freenome Appoints Rob Guigley as Chief Commercial Officer, Prepares for Commercial Launch of Cancer Tests.
ByAinvest
Monday, Nov 10, 2025 7:06 am ET1min read
EXAS--
Freenome has appointed industry veteran Rob Guigley as Chief Commercial Officer to drive commercial strategy. The appointment comes as the company's agreement with Exact Sciences clears antitrust review. Guigley will lead the execution of the exclusive U.S. licensing and commercialization of Freenome's colorectal cancer blood-based screening tests and build out the company's core commercial capabilities. The FDA is reviewing the Premarket Approval Application for the initial version of the test, with approval expected in H2 2026.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet